Zebrafish Pharmacokinetic Analysis Service

BioVenic delivers full-process standardized zebrafish absorption, distribution, metabolism, and excretion (ADME) analysis services, supporting preclinical drug dosage optimization, metabolite identification, blood-brain barrier evaluation and drug interaction mechanism research. Zebrafish pharmacokinetic testing serves as a credible in vivo preclinical approach to quantify the absorption, distribution, metabolism and excretion of small-molecule drugs and novel compounds. With high genetic similarity to humans, transparent embryos and diverse administration modes, zebrafish can accurately recapitulate real-time metabolic behaviors of drugs in living organisms.

Ideal Projects We Support

• Novel Candidate Drug ADME Preliminary Screening: Conduct full pharmacokinetic profiling of new small-molecule compounds, evaluate bioavailability, metabolic stability and excretion efficiency, and screen high-quality lead compounds for follow-up drug development.
• Central Nervous System Drug Penetration Research: Focus on neuropharmaceutical research, detect blood-brain barrier crossing efficiency and brain tissue enrichment, providing data support for neurodrug efficacy optimization.
• Combined Medication and DDI Mechanism Exploration: Analyze metabolic enzyme changes and competitive metabolic effects between drugs, clarify DDI rules to guide safe combined medication design.
• Drug Formulation and Administration Route Optimization: Evaluate absorption efficiency of oral, injection and immersion administration, optimize dosing frequency and dosage to reduce cumulative toxic side effects.

Fig 1. Advantages of zebrafish as a model organism. ¹

Common Challenges We Help Address

• Extremely low in vivo drug content in zebrafish tissues leads to difficult trace compound detection, easily causing inaccurate quantification of metabolic parameters such as half-life and clearance rate.
• Individual differences in liver metabolic enzyme activity of larvae result in inconsistent drug metabolic rates, interfering with the stability of ADME experimental data.
• Fluorescent labeling for drug localization may interfere with drug activity and tissue distribution, affecting the authenticity of in vivo tracking results.
• Short drug metabolic cycle requires high-frequency dynamic sampling, and improper operation easily causes sample loss and data deviation.
• Complex in vivo tissue microenvironment easily leads to drug non-specific adsorption, affecting accurate judgment of effective drug distribution concentration.

Zebrafish Pharmacokinetic Analysis Service

• Absorption Analysis

Applicable Scenarios: In vivo drug bioavailability evaluation. Suitable for detecting the absorption efficiency of oral, transdermal and immersion-administered drugs, and screening optimal absorption modes for candidate compounds.

Technical Capabilities: Establish multiple administration models, dynamically detect in vivo plasma and tissue drug concentration changes, calculate drug absorption rate and bioavailability parameters, and compare absorption differences of different administration routes.

Deliverables: Drug absorption dynamic curve, bioavailability statistical data, absorption efficiency comparison results and administration route optimization suggestions.

• Distribution Analysis

Applicable Scenarios: In vivo drug tissue localization and barrier penetration detection. Focus on organ-specific drug distribution and blood-brain barrier crossing capability evaluation for central nervous system drugs.

Technical Capabilities: Adopt fluorescent and radiolabeled tracing technology, observe real-time drug tissue enrichment, quantify drug distribution ratios in liver, brain and other key organs, and evaluate BBB penetration efficiency.

Deliverables: Whole-body drug distribution imaging atlas, organ concentration distribution data, BBB penetration rate statistics and tissue distribution characteristics analysis report.

• Metabolism Analysis

Applicable Scenarios: Drug metabolic pathway exploration and metabolite identification. Applied to analyze liver-dependent drug metabolism rules and evaluate compound metabolic stability in vivo.

Technical Capabilities: Combine high-precision mass spectrometry detection to identify drug intermediate metabolites, monitor metabolic enzyme activity changes, and clarify key metabolic pathways and metabolic transformation characteristics of target drugs.

Deliverables: Metabolite identification data, metabolic pathway mapping, metabolic stability evaluation results and liver metabolic characteristic analysis report.

• Excretion Analysis

Applicable Scenarios: Drug elimination dynamic rule evaluation. Suitable for calculating in vivo drug half-life, renal excretion rate and clearance capacity, judging drug in vivo retention and elimination efficiency.

Technical Capabilities: Conduct continuous dynamic sampling and detection, fit drug concentration-time curve, calculate core excretion kinetic parameters, and evaluate drug cumulative retention risk in vivo.

Deliverables: Drug excretion kinetic parameters, half-life fitting data, renal excretion rate statistics and in vivo drug elimination capacity evaluation conclusion.

• Drug-drug Interaction (DDI) Evaluation

Applicable Scenarios: Combined medication safety and metabolic interaction research. Used to explore competitive metabolism and metabolic enzyme interference between multiple drugs in vivo.

Technical Capabilities: Design single and combined drug administration groups, detect changes in metabolic enzyme activity and drug metabolic rate, analyze synergistic or antagonistic metabolic interactions between compounds.

Deliverables: DDI experimental comparison data, metabolic enzyme activity difference analysis, drug competitive metabolism mechanism summary and combined medication safety evaluation report.

• Toxicity and Safety Evaluation

Applicable Scenarios: Drug metabolic cumulative toxicity and organ safety assessment. Suitable for evaluating adverse reactions such as organ damage and developmental toxicity caused by long-term drug accumulation.

Technical Capabilities: Combine ADME dynamic data with phenotypic observation, monitor drug-induced organ toxicity and developmental abnormalities, and correlate drug accumulation concentration with toxic effects.

Deliverables: Drug cumulative toxicity data, organ safety assessment results, developmental toxicity phenotypic statistics and comprehensive medication risk analysis report.

Standardized Service Workflow

All zebrafish pharmacokinetic tests follow BioVenic exclusive standardized operating specifications to ensure high accuracy and repeatability of ADME kinetic data.

1. Experimental Model Grouping: Screen healthy zebrafish embryos and larvae with consistent developmental status, set blank control and gradient drug concentration groups to unify experimental baseline.
2. Standardized Drug Administration: Select immersion, injection or oral administration according to research demands, conduct standardized drug intervention and timing recording.
3. Dynamic Sample Collection & Imaging: Perform high-frequency timed sampling and real-time fluorescence imaging to track in vivo drug distribution and concentration dynamic changes.
4. ADME Index Quantitative Detection: Complete drug absorption, distribution, metabolism and excretion index testing, identify metabolites and calculate kinetic parameters.
5. Drug Interaction & Safety Verification: Analyze DDI effects and evaluate organ cumulative toxicity risks combined with metabolic data.
6. Data Fitting & Report Output: Fit pharmacokinetic curves, summarize ADME rules, and deliver standardized preclinical pharmacokinetic analysis reports.

Why Choose BioVenic

• Professional Pharmacokinetic Research Team: Specialized in zebrafish preclinical ADME research, proficient in drug kinetic parameter fitting, metabolite identification and DDI mechanism interpretation with rich pharmaceutical research experience.
• PK-Tailored Customized Solutions: Flexibly design administration modes, sampling cycles and detection indicators according to drug properties, adapting to high-throughput screening and in-depth mechanism research demands.
• Visualized In Vivo Detection Technology: Equipped with high-precision fluorescence imaging and mass spectrometry detection platforms, realizing intuitive drug distribution tracking and trace metabolite quantitative analysis.
• Preclinical Research-Oriented Output: All data conforms to preclinical drug research specifications, providing reliable basic data for compound optimization, patent application and academic publication.

Core Application Scenarios

• Early-Stage New Drug Screening

Rapidly complete ADME preliminary evaluation of candidate compounds, eliminate drugs with poor metabolic stability and low bioavailability, and accelerate drug screening progress.

• Neuropharmaceutical Development

Evaluate the blood-brain barrier penetration ability of central nervous system drugs, optimize drug brain targeting efficiency and therapeutic effect.

• Clinical Combined Medication Guidance

Clarify drug-drug interaction metabolic rules, avoid competitive metabolism-induced drug failure or toxic enhancement, and guide rational combined medication.

• Dosage Regimen Optimization

Based on pharmacokinetic parameters such as half-life and clearance rate, optimize clinical administration dosage and frequency to improve medication safety and efficacy.

Case Study: In Vivo PK Profiling and BBB Penetration Evaluation of Compound A in Adult Zebrafish

This is a standardized pharmacokinetic case study independently developed and completed by BioVenic. Using wild-type adult zebrafish as in vivo models, we administered Compound A via intraperitoneal injection and quantified its dynamic concentrations in serum and brain tissues through LC-MS/MS. Core non-compartmental pharmacokinetic parameters were calculated to characterize the drug's absorption, distribution and elimination profiles, and its favorable blood-brain barrier penetration capacity was verified. The stable and reproducible experimental system provides a standardized paradigm for preclinical PK screening of small-molecule CNS drugs.

Fig 2. Concentration-time profiles of Compound A in zebrafish serum and brain tissue.

Fig 3. Comparison of Cmax and AUC0-inf of Compound A in zebrafish serum and brain tissue.

Frequently Asked Questions

1. What core pharmacokinetic parameters can be detected in this service?
   Our service covers core ADME indicators including drug bioavailability, tissue distribution ratio, metabolite species, half-life, clearance rate and renal excretion rate, supporting complete kinetic parameter fitting.
2. Why are zebrafish suitable for early preclinical PK screening?
   Zebrafish has high human genetic homology, complete metabolic systems and high-throughput screening characteristics, which can quickly verify drug metabolic rules and make up for the low efficiency of mammalian model early screening.
3. Can this service evaluate blood-brain barrier penetration of drugs?
   Yes. We adopt fluorescence tracing and quantitative tissue detection technology to accurately calculate drug brain enrichment concentration and BBB penetration efficiency, especially applicable for neurodrug development.
4. What is the difference between DDI evaluation and single drug PK test?
   Single drug test focuses on independent ADME characteristics of compounds, while DDI evaluation focuses on metabolic enzyme interference and competitive metabolic effects between multiple drugs to guide combined medication safety.
5. What administration routes are supported for PK analysis?
   We support multiple standardized administration methods including immersion administration, microinjection and oral administration, which can be selected according to drug solubility and research design.

Partner with BioVenic

BioVenic offers robust and tailored Zebrafish Pharmacokinetic Analysis Service to streamline your preclinical drug evaluation and aquatic drug research. We know that precise pharmacokinetic profiling is essential for deciphering drug absorption, distribution, metabolism and excretion in zebrafish models, laying a solid foundation for drug efficacy and safety verification. Our skilled professionals adhere to rigorous experimental standards to generate credible, high-quality PK data for your research advancement. For personalized project solutions, in-depth technical consultation, or an exclusive service quote, please contact us. Our dedicated team is on hand to support and optimize your zebrafish pharmacokinetic research projects.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services